Search - tctmd.com

Displaying 1 - 1 of 1

Sort: Relevancy | Date

A Randomized Evaluation oF the TriGUARD3™ Cerebral Embolic Protection Device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation The REFLECT II Trial

Presentation TCT 2020

A Randomized Evaluation oF the TriGUARD3™ Cerebral Embolic Protection Device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation The REFLECT II Trial

Presenter: Jeffrey W. Moses

October 15, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.